Skip to contentP
Perspective Therapeutics, Inc.
P
CATXPerspective Therapeutics, Inc. Q3 2025 · 10-Q
Revenue—
Net Income-$25.97M-$25.97MN/M vs Q3 2024 EPS Diluted-$0.35-$0.35N/M vs Q3 2024 Operating Income-$27,861,000N/M Operating Cash Flowderived-$16,292,000N/M
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Perspective Therapeutics, Inc. · CIK 728387 · Engraved from SEC EDGAR
Free Cash Flowderived-$18,284,000N/M ended Sep 30, 2025 · filed Nov 10, 2025 · 41 d after period end